BUSINESS

• Nippon Kayaku’s Novel DDS Formulation of Paclitaxel Disappoints in PIII for Breast Cancer
  July 6, 2016

• Takeda Gains Rights to TiGenix’s Cx601 Stem Cell Treatment Outside US
  July 6, 2016

• Delving into Securities Filings - 3: Six Companies Report Higher Pay, More Employees
  July 6, 2016

• Delving into Securities Filings - 2: Average Annual Pay at 3 Generic Majors Tops 7 Mil. Yen
  July 5, 2016

• Takeda Gets Option to Acquire US Developer of Gastroparesis Treatment
  July 5, 2016

• Takeda Files for Japan Approval of MM Drug Ixazomib
  July 5, 2016

• Belsomra Comes Back to Top Position in GP Market: Anterio
  July 4, 2016

• Delving into Securities Filings - 1: 1st and 2nd-Tier Makers Continue to Shed Jobs as Generic Peers See Rise in Workforce
  July 4, 2016

• Sanofi Japan Completes Merger of Genzyme Japan
  July 4, 2016

• Eisai Gives Global R&D Updates on Dementia, Oncology
  July 1, 2016

• Filing for 1st Japan-Made Nucleic Acid Expected by Year-End If PIII Yields Positive Data
  July 1, 2016

• Toho Holdings Appoints Ex-Qol Exec Takada as Senior Executive Officer
  July 1, 2016

• Nichi-Iko Aims for 20% Share of Generic Market in “80% Generic Era”: President
  June 30, 2016

• Kyowa Kirin’s KRN23 Gets BT Designation for X-Linked Hypophosphatemia in Children
  June 30, 2016

• Novel Anti-HIV Agent Genvoya to Hit Japan Market on July 8: JT, Torii
  June 30, 2016

• Celgene Files Revlimid for ATL in Japan
  June 30, 2016

• Reconsider Appropriate Diabetes Drug Combos Including GLP-1 Agents: Diabetologist
  June 29, 2016

• MSD Initiates Long-Term Observational Study of Treatment with Oral Hypoglycemic Agents
  June 29, 2016

• Boehringer-Sanofi Asset Swap Slated to Close by Year’s End; Fate of Japan Units Subject to Future Discussions
  June 28, 2016

• Daiichi Sankyo, Servier Sign Sales Accord for Edoxaban in Canada
  June 28, 2016

ページ

• « 先頭
• ‹ Prev
• …
• 476
• 477
• 478
• 479
• 480
• 481
• 482
• 483
• 484
• …
• Next ›
• 最終 »